Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients

Journal of Neuroimmunology

Volumn 264, Issue 1-2, 2013, Pages 114-119

  Kohler, Siegfried ^a   Keil, Thomas Oskar Philipp ^a   Swierzy, Marc ^a   Hoffmann, Sarah ^a   Schaffert, Hanne ^a   Ismail, Mahmoud ^a   Rückert, Jens Carsten ^a   Alexander, Tobias ^a   Hiepe, Falk ^a   Gross, Christian ^b   Thiel, Andreas ^a   Meisel, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

Autoimmunity; B cells; Immunology; Myasthenia gravis; Plasma cells

Indexed keywords

ADULT; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL ACTIVATION; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MYASTHENIA GRAVIS; PLASMA CELL; PRIORITY JOURNAL;

AUTOIMMUNITY; B CELLS; IMMUNOLOGY; MYASTHENIA GRAVIS; PLASMA CELLS;

AGED; ANTIGENS, CD; B-LYMPHOCYTE SUBSETS; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PLASMA CELLS;

EID: 84886782632     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.09.006     Document Type: Article

References (36)

1. Berrih-Aknin S., Ragheb S., Le Panse R., Lisak R.P. Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. Autoimmun. Rev. 2013, 12.
2. Bever C.T., Aquino A.V., Penn A.S., Lovelace R.E., Rowland L.P. Prognosis of ocular myasthenia. Ann. Neurol. 1983, 14:516-519.
3. Cavalcante P., Serafini B., Rosicarelli B., Maggi L., Barberis M., Antozzi C., Berrih-Aknin S., Bernasconi P., Aloisi F., Mantegazza R. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann. Neurol. 2010, 67:726-738.
4. Cavalcante P., Le Panse R., Berrih-Aknin S., Maggi L., Antozzi C., Baggi F., Bernasconi P., Mantegazza R. The thymus in myasthenia gravis: site of "innate autoimmunity"?. Muscle Nerve 2011, 44:467-484.
5. Grob D., Arsura E.L., Brunner N.G., Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann. N. Y. Acad. Sci. 1987, 505:472-499.
6. Huang W., Sinha J., Newman J., Reddy B., Budhai L., Furie R., Vaishnaw A., Davidson A. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 2002, 46:1554-1562.
7. Jacobi A.M., Odendahl M., Reiter K., Bruns A., Burmester G.R., Radbruch A., Valet G., Lipsky P.E., Dorner T. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003, 48:1332-1342.
8. Jacobi A.M., Mei H., Hoyer B.F., Mumtaz I.M., Thiele K., Radbruch A., Burmester G.R., Hiepe F., Dorner T. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2010, 69:305-308.
9. Kaminski H.J., Cutter G., Ruff R. Practice parameters and focusing research: plasma exchange for myasthenia gravis. Muscle Nerve 2011, 43:625-626.
10. + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 1998, 188:1679-1689.
11. Klooster R., Plomp J.J., Huijbers M.G., Niks E.H., Straasheijm K.R., Detmers F.J., Hermans P.W., Sleijpen K., Verrips A., Losen M., Martinez-Martinez P., De Baets M.H., van der Maarel S.M., Verschuuren J.J. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012, 135:1081-1101.
12. Kohler S., Bethke N., Bothe M., Sommerick S., Frentsch M., Romagnani C., Niedrig M., Thiel A. The early cellular signatures of protective immunity induced by live viral vaccination. Eur. J. Immunol. 2012, 42:2363-2373.
13. Kupersmith M.J. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J. Neurol. 2009, 256:1314-1320.
14. Kupersmith M.J., Moster M., Bhuiyan S., Warren F., Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch. Neurol. 1996, 53:802-804.
15. Kupersmith M.J., Latkany R., Homel P. Development of generalized disease at 2years in patients with ocular myasthenia gravis. Arch. Neurol. 2003, 60:243-248.
16. Li H., Shi F.D., He B., Bakheit M., Wahren B., Berglof A., Sandstedt K., Link H. Experimental autoimmune myasthenia gravis induction in B cell-deficient mice. Int. Immunol. 1998, 10:1359-1365.
17. Li X., Xiao B.G., Xi J.Y., Lu C.Z., Lu J.H. Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis. Clin. Immunol. 2008, 126:180-188.
18. Luchanok U., Kaminski H.J. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr. Opin. Neurol. 2008, 21:8-15.
19. Mee J., Paine M., Byrne E., King J., Reardon K., O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J. Neuroophthalmol. 2003, 23:251-255.
20. Monsul N.T., Patwa H.S., Knorr A.M., Lesser R.L., Goldstein J.M. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J. Neurol. Sci. 2004, 217:131-133.
21. Odendahl M., Jacobi A., Hansen A., Feist E., Hiepe F., Burmester G.R., Lipsky P.E., Radbruch A., Dorner T. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 2000, 165:5970-5979.
22. Odendahl M., Mei H., Hoyer B.F., Jacobi A.M., Hansen A., Muehlinghaus G., Berek C., Hiepe F., Manz R., Radbruch A., Dorner T. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005, 105:1614-1621.
23. Osserman K.E., Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt. Sinai J. Med. 1971, 38:497-537.
24. Ragheb S., Lisak R.P. Effect of clinical status and treatment on the frequency of CD5+ B cells in patients with myasthenia gravis. Neurology 1992, 42:1076-1080.
25. Ragheb S., Bealmear B., Lisak R. Cell-surface expression of lymphocyte activation markers in myasthenia gravis. Autoimmunity 1999, 31:55-66.
26. Rodriguez-Bayona B., Ramos-Amaya A., Perez-Venegas J.J., Rodriguez C., Brieva J.A. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res. Ther. 2010, 12:R108.
27. Scadding G.K., Vincent A., Newsom-Davis J., Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 1981, 31:935-943.
28. Schumm F., Fateh-Moghadam A., Dichgans J. Correlation of acetylcholine receptor antibodies and clinical severity of myasthenia gravis in combined immunosuppressive therapy. Eur. Arch. Psychiatry Neurol. Sci. 1984, 234:224-230.
29. Shi F.D., He B., Li H., Matusevicius D., Link H., Ljunggren H.G. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur. J. Immunol. 1998, 28:3587-3593.
30. Sommer N., Sigg B., Melms A., Weller M., Schepelmann K., Herzau V., Dichgans J. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J. Neurol. Neurosurg. Psychiatry 1997, 62:156-162.
31. Toyka K.V., Brachman D.B., Pestronk A., Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 1975, 190:397-399.
32. Vincent A., Scadding G.K., Thomas H.C., Newsom-Davis J. In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet 1978, 1:305-307.
33. Wei C., Anolik J., Cappione A., Zheng B., Pugh-Bernard A., Brooks J., Lee E.H., Milner E.C., Sanz I. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J. Immunol. 2007, 178:6624-6633.
34. Willcox H.N., Newsom-Davis J., Calder L.R. Greatly increased autoantibody production in myasthenia gravis by thymocyte suspensions prepared with proteolytic enzymes. Clin. Exp. Immunol. 1983, 54:378-386.
35. Yi Q., Ahlberg R., Pirskanen R., Lefvert A.K. Levels of CD5+ B lymphocytes do not differ between patients with myasthenia gravis and healthy individuals. Neurology 1992, 42:1081-1084.
36. Yurasov S., Wardemann H., Hammersen J., Tsuiji M., Meffre E., Pascual V., Nussenzweig M.C. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 2005, 201:703-711.